Merck & Company Inc (MRK)vsPrime Medicine, Inc. Common Stock (PRME)
MRK
Merck & Company Inc
$144.70
-2.49%
HEALTHCARE · Cap: $368.89B
PRME
Prime Medicine, Inc. Common Stock
$4.55
+2.48%
HEALTHCARE · Cap: $654.77M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1654160% more annual revenue ($67.38B vs $4.07M). MRK leads profitability with a 3.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
PRME
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$144.70
$60.04 premium
Margin of Safety
-44.4%
Fair Value
$2.39
Current Price
$4.55
$2.16 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
No standout strengths identified
Areas to Watch
Trading at 8.5x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Trading at 19.8x book value
3.5% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PRME
PRME has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : PRME
The primary concerns for PRME are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 2.83 is elevated, increasing financial risk.
Key Dynamics to Monitor
PRME carries more volatility with a beta of 2.38 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (44/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Prime Medicine, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA modifications. The firm has curated a diverse pipeline targeting severe diseases, including genetic disorders and various cancers, addressing substantial unmet medical needs within the healthcare system. With a strong intellectual property foundation and a commitment to developing innovative therapeutic solutions, Prime Medicine is strategically positioned for notable growth and has the potential to significantly change therapeutic approaches in the biopharmaceutical industry.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?